Lobular Breast Cancer Alliance (LBCA) Scientific Advisory Board members Dr. Jason Mouabbi and Dr. Gary Ulaner were part of the recent process of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) to develop appropriate use criteria (AUC) for Positron Emission Tomography (PET) imaging with 16α- 18F-fluoro-17β-fluoroestradiol (18F-FES) (known as FES/PET) in the care of patients with estrogen receptor positive breast cancer.
They recently recorded a video to explain what an AUC is and how it is developed, what the new AUC for Fluoroestradiol is, how AUCs are useful for clinicians and patients with lobular breast cancer, and how AUCs relate to other established clinical guidelines such as the National Comprehensive Cancer Network (NCCN) guidelines for breast cancer treatment. Dr. Ulaner also tells us how patient advocates can make recommendations to NCCN for certain data or publications to be considered for their guidelines.
A fact sheet describing the AUC for FES/PET is also available to read.
Watch the video below and stay tuned for more information on LBCA and SNMMI’s first joint ILC imaging research grant.